This report was first published by Endpoints News. To see the original version, click here
Biopharma industry lobby groups working to keep the pipeline open for plentiful, lower-cost drugs coming from China have awakened to the fact that they face a vocal opposition and a growing set of anti-China proposals in Congress.
On Wednesday representatives from the drug lobby group PhRMA met with staff of the Select Committee on China, multiple sources told Endpoints News. Chaired by Rep. John Moolenaar (R-MI), who introduced a bill monitoring outbound investments into China biotech alongside Rep. Debbie Dingell (D-MI), the committee has been at the center of the hawkish policies that some in industry are trying to combat.
您已阅读12%（722字），剩余88%（5160字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。